Engagement and collaboration with EU scientific and research policies, networks and projects on behalf of hematologists in a way that benefits all sides – researchers, diagnosticians and clinicians as well as policymakers and regulators – is an important part of EHA’s European Affairs work.
Amongst others, EHA:
- Monitors relevant legislative and regulatory developments affecting hematologists, and tries to influence them including through the direct involvement of experts in policy or regulatory processes.
- Monitors and alerts its members to EU funding opportunities that could benefit hematology researchers or research groups.
- Helps the European Medicines Agency (EMA) and other regulatory or HTA bodies identify leading experts to assist with assessments, both pre- and post-licensing, of medicines and therapies.
- EHA actively contributes to the creation of, participates in, or supports European scientific networks. These can be hematology-specific or cross-disciplinary in nature, often resulting from EU-funded projects or public-private partnerships.
Close interaction with the EHA Specialized Working Groups helps EHA to effectively advocate for the interests of researchers and clinicians in EU context, flag relevant calls for proposals, signal opportunities for collaboration, and support policymakers, regulators and payers in need of the best available scientific advice.
For information on some of the key scientific networks supported by EHA, see this link.